araag2/HINT huggingface dataset:
Clinical trial NCT01060904 (phase 1, status: completed)
Conditions: disease, hodgkin
ICD codes: C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70
Drugs: brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin, brentuximab vedotin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, N1C=CN=C1, C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment-naive Hodgkin lymphoma, Stage IIa or IIb-IV

          -  Measurable disease of at least 1.5 cm

          -  Eastern Cooperative Oncology Group performance status <3

        Exclusion Criteria:

          -  History of another primary malignancy that has not been in remission for at least 3
             years

          -  Known cerebral/meningeal disease
Clinical trial NCT00579137 (phase 1/phase 2, status: terminated)
Conditions: severe combined immunodeficiency disease, severe primary immunodeficiency disorder, undefined t cell deficiency disorder, wiskott-aldrick syndrome
ICD codes: D81.0, D81.31, D81.1, D81.2, D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822, D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

        - Patients with a diagnosis of: Severe combined immunodeficiency disease

        This includes patients whose SCID is characterized by gene specific mutations as well as
        patients with clinically severe combined immunodeficiency without a defined genetic cause
        in which the diagnosis will be determined by a combination of clinical course with
        lymphocyte quantification and function assays.

        OR

        Severe primary immunodeficiency disorder, including undefined T cell deficiency disorder,
        Wiskott-Aldrich syndrome, and other severe immunodeficiencies for which satisfactory
        conventional therapy does not exist.

          -  Availability of an HLA mismatched (up to one haplotype) family member or an HLA
             matched or mismatched (up to one antigen) unrelated donor.

          -  Creatinine < 2.5 x normal for age.

          -  Life expectancy greater than 6 weeks

          -  Lansky/Karnofsky greater than or equal to 70%

        Exclusion Criteria:

          -  Patients with an HLA matched related donor

          -  Patients with symptomatic cardiac disease, or evidence of significant cardiac disease
             by echocardiogram (i.e., shortening fraction less than 25%)

          -  Patients with known allergy to rat serum products

          -  Patients with a severe infection that on evaluation by the Principal Investigator
             precludes ablative chemotherapy or successful transplantation

          -  HIV positive

          -  Pregnant
Clinical trial NCT01292135 (phase 1, status: completed)
Conditions: b-cell chronic lymphocytic leukemia, small lymphocytic lymphoma
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pci-32765
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed CLL or SLL and satisfying at least 1 of the following
             criteria for requiring treatment:

               -  Progressive splenomegaly and/or lymphadenopathy identified by physical
                  examination or radiographic studies

               -  Anemia (<11 g/dL) or thrombocytopenia (<100,000/μL) due to bone marrow
                  involvement

               -  Presence of unintentional weight loss > 10% over the preceding 6 months

               -  NCI CTCAE Grade 2 or 3 fatigue

               -  Fevers > 100.5° or night sweats for > 2 weeks without evidence of infection

               -  Progressive lymphocytosis with an increase of > 50% over a 2 month period or an
                  anticipated doubling time of < 6 months

          2. 1 to 3 prior treatment regimens for CLL/SLL

          3. ECOG performance status of ≤ 1

          4. ≥ 18 years of age

          5. Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty

          6. Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject privacy regulations)

        Exclusion Criteria:

          1. Any chemotherapy, therapeutic antineoplastic antibodies (not including radio- or toxin
             immunoconjugates), radiation therapy, or experimental antineoplastic therapy within 4
             weeks of first dose of study drug

          2. Radio- or toxin-conjugated antibody therapy within 10 weeks of first dose of study
             drug

          3. Concomitant use of medicines known to cause QT prolongation or torsades de pointes

          4. Transformed lymphoma or Richter's transformation Any life-threatening illness, medical
             condition or organ system dysfunction which, in the investigator's opinion, could
             compromise the subject's safety, interfere with the absorption or metabolism of
             PCI-32765 PO, or put the study outcomes at undue risk

          5. Any of the following laboratory abnormalities: oAbsolute neutrophil count (ANC) < 1000
             cells/mm3 (1.0 x 109/L) oPlatelet count < 50,000/mm3 (50 x 109/L) oSerum aspartate
             transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x upper limit of
             normal (ULN) oCreatinine > 2.0 x ULN or creatinine clearance < 40 mL/min
Clinical trial NCT01843972 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: bi 691751, bi 691751, placebo, bi 691751, bi 691751, bi 691751, bi 691751, bi 691751, bi 691751, bi 691751
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Healthy male subjects

          2. Subjects must be able to understand and comply with study requirements

          3. Age from 18 to 55 years

          4. BMI range: from 18.5 to 29.9 kg/m2

          5. Known genotype as specified in the study protocol

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
Clinical trial NCT00078390 (phase 1/phase 2, status: completed)
Conditions: non small cell lung cancer, lung cancer, stage iiia non small cell lung cancer, stage iiib non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: s-3304
SMILES: CC1=CC=C(C=C1)C#CC1=CC=C(S1)S(=O)(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(O)=O
Eligibility criteria:

        INCLUSION CRITERIA

          -  newly diagnosed non-small cell lung cancer of stage IIIA non-resectable or of stage
             IIIB without pleural effusion

          -  ECOG performance status 0-1

          -  adequate organ function

          -  clinically indicated and able to receive conventional chemoradiation therapy

        EXCLUSION CRITERIA

          -  patients with prior history of cancer, other than basal cell carcinoma after
             appropriate treatment, or prior systemic chemotherapy treatment

          -  patients with other serious intercurrent illness including HIV/AIDS, or
             contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment
Clinical trial NCT01404390 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bay80-6946, bay80-6946
SMILES: COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21, COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
Eligibility criteria:

        Inclusion Criteria:

          -  Cancer patients

          -  Japanese patients, who are at least 20 years of age

          -  Histological or cytological documentation of non-hematologic, malignant solid tumours,
             excluding primary brain or spinal tumours, with no past or current involvement in the
             central nervous system (CNS)

          -  At least one measurable lesion or evaluable disease according to RECIST (version 1.1)

          -  Eastern Cooperative Oncology performance status (ECOG-PS) of 0 or 1

          -  Life expectancy of at least 12 weeks

          -  Advanced or refractory solid tumours not amenable to standard therapy, at the first
             screening examination/visit

        Exclusion Criteria:

          -  Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of first
             study treatment. Patients must have recovered from the toxic effects of the previous
             anti-cancer chemotherapy or immunotherapy by the investigator (with the exception of
             alopecia).

          -  Radiotherapy to target lesions during study or within 4 weeks of first study treatment

          -  Investigational drug therapy outside of this trial during or within 4 weeks of first
             study treatment

          -  Current diagnosis of Type I or II diabetes mellitus or fasting blood glucose level
             >125 mg/dL at screening, and/or HbA1c>/= 6.5%

          -  Past and current histories of cardiac disease congestive heart failure > New York
             Heart Association (NYHA) Class II; active coronary artery disease, myocardial
             infarction within 6 months prior to study entry; new onset of angina within 3 months
             prior to study entry or unstable angina or ventricular cardiac arrhythmias requiring
             anti-arrhythmic therapy

          -  Active and clinically serious infections >Grade 2 (National Cancer Institute Common
             Terminology Criteria for Adverse Events [NCI-CTCAE] version 4.03)

          -  Uncontrolled hypertension defined as systolic blood pressure >150 mm Hg or diastolic
             pressure > 90 mm Hg, despite optimal medical management

          -  Patients undergoing renal dialysis

          -  Pregnant or breast feeding women
Clinical trial NCT00709722 (phase 1/phase 2, status: completed)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: nkt-01
SMILES: NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged 18-70 years.

          -  A diagnosis of SLE according to the ACR criteria (at least 4/11 criteria).

          -  Sufficient signs to diagnose active SLE nephritis.

          -  Serum creatinine concentration of <= 5.0 mg/dL.

          -  Leucocyte counts >= 4000/uL.

          -  Receiving OCS (<= 1.0 mg/kg/day; a maximum dose of 80 mg/day).

          -  Prior treatment with cyclophosphamide, azathioprine, cyclosporin A, or any other
             immunosuppressive drugs.

        Exclusion Criteria:

          -  Chronic infection of HIV, Hepatitis B, Hepatitis C.

          -  Acute infection including fungal, viral, bacterial or protozoal diseases.

          -  Liver toxicity (WHO CTC class 2 and higher). No adequate liver function (total
             bilirubin > 25 umol/L = 1.4 mg/dL unless explained otherwise (e.g. inherited,
             hemolysis), SGOT > 2.5 x N, SGPT > 2.5 x N).

          -  Pregnant or lactating women

          -  Female patients of child bearing age without safe method of contraception.

          -  Anemia (hemoglobin < 8.0 g/dL), leucopenia (leucocytes < 4000/uL unless attributable
             to SLE: leucocytes < 2000/uL), thrombocytopenia (platelets < 50000/uL).

          -  Neutrophils below 1000/uL.

          -  Hypogammaglobulinemia below 400 mg/dL of serum IgG.

          -  Any other condition that in the eyes of the investigator might have rendered the
             patient unsuitable for participation in the study. This especially includes major and
             active SLE organ involvement other than the kidney. Patients with SLE involvement of
             the central nervous system are not allowed to be included into the study.

          -  History of malignancy.

          -  Current participation in another trial or lass than 6 months since participation in a
             similar trial.
Clinical trial NCT01188317 (phase 1, status: completed)
Conditions: healthy volunteer
ICD codes: Y99.2
Drugs: aleglitazar, placebo, ibuprofen
SMILES: CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy volunteers, aged 40 to 65 years inclusive

          -  Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive

          -  Females of child-bearing potential must be willing to use two acceptable methods of
             contraception during the study and at least 3 months before start of the study

          -  Non-smoker or currently smoking less than 5 cigarettes (or equivalent amount of other
             tobacco products) per day and is willing and able to stop smoking during the period in
             study center

          -  Volunteer drinks no more than 3 cups of coffee, tea or soft drinks per day and is
             willing and able to stop drinking coffee, tea and soft drinks during the period in
             study center

        Exclusion Criteria:

          -  Any clinically relevant abnormal laboratory test results at screening

          -  Volunteer has taken any prescribed, herbal or over-the-counter medication within 2
             weeks prior to first dosing

          -  A history of any clinical significant gastro-intestinal, cardiovascular,
             musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic,
             bronchopulmonary or neurological conditions or lipid disorders

          -  A positive test for human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B or
             hepatitis C

          -  History of intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin,
             history of gastric or duodenal ulceration, personal or family history of abnormal
             clotting or bleeding
Clinical trial NCT01016223 (phase 1, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: beclomethasone dipropionate, placebo
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects 18 years of age or older with biopsy proven diagnosis of EoE.

          -  Subjects who are able and willing to provide consent for repeat EGDs with esophageal
             biopsies, and blood work as per study protocol.

        Exclusion criteria:

          -  Subjects with suspected or proven inflammatory bowel disease, malignancy, and
             collagen-vascular disease.

          -  Subjects who have used oral, inhaled or swallowed corticosteroids in the past 3
             months.

          -  Subjects who are pregnant or breastfeeding

          -  Subjects who are not able to swallow beclomethasone or are intolerant to the
             medication.

          -  Subjects with history of ischemic heart disease, diabetes and dyslipidemia unless they
             have been stable in the last six months.
Clinical trial NCT00489359 (phase 1/phase 2, status: completed)
Conditions: ovarian cancer, primary peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: pemetrexed - phase 1, carboplatin - phase 1, pemetrexed - phase 2, carboplatin - phase 2
SMILES: [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ovarian or primary peritoneal cancer confirmed by pathology

          -  Patients must have recurrent ovarian cancer which is sensitive to platinum therapy

          -  Prior radiation therapy is allowed

        Measurable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST)
        guidelines, or non-measurable but cancer antigen 125 (CA-125) greater than or equal to 2X
        upper limit.

        Exclusion Criteria:

          -  More than 2 lines of therapy for ovarian or primary peritoneal cancer.

          -  Pregnant or breast feeding.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.
Clinical trial NCT00862836 (phase 1/phase 2, status: terminated)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: vandetanib
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologically documented invasive epithelial ovarian carcinoma, cancer of the
             fallopian tube or the peritoneum refractory to platinum-based chemotherapy or with
             partially platinum sensitive disease.

          -  Planned therapy with pegylated liposomal doxorubicin 50 mg/m² for recurrent
             platinum-refractory ovarian cancer.

          -  Patients with a progression-free-interval of 6 to 12 months after platinum-based
             chemotherapy are only eligible if a further course of platinum-based combination
             chemotherapy is not possible as judged by the investigator(s).

          -  Patients must have received at least one previous platinum- and taxane-based
             chemotherapy regimen.

        Exclusion Criteria:

          -  Brain metastases or spinal cord compression, unless treated at least 4 weeks before
             first dose and stable without steroid treatment for 10 days

          -  Any concomitant medications that may cause QTc prolongation or induce Torsades de
             Pointes or induce CYP3A4 function

          -  Treatment with mouse-antibodies in patients with evaluable disease and CA-125
             progressive disease in the last 3 months. These patients are only eligible in case of
             measurable disease according to RECIST or cytological/histological proven relapse

          -  More than two prior lines of chemotherapy.

          -  Any chemotherapy or other systemic anti-cancer therapy within four weeks prior to
             randomization.

          -  Radiation therapy within the last 4 weeks prior to randomization (with the exception
             of palliative radiotherapy
Clinical trial NCT02256761 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: birt 2584 xx - multiple escalating dose, placebo, birt 2584 xx - single dose
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male subjects as determined by results of the screening

          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and
             local legislation

          -  Age ≥ 18 and ≤ 63 years

          -  BMI ≥ 18.5 and ≤ 29.9 kg/m2

        Exclusion Criteria:

          -  Any finding during the medical examination (including blood pressure, pulse rate, and
             electrocardiogram) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic,
             hematological, oncological, or hormonal disorders

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Relevant history of orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) considered relevant to
             the trial as judged by the investigator

          -  Intake of drugs with a long half-life (greater than 24 hours) (less than 1 month prior
             to administration or during the trial)

          -  Use of any drugs, which might influence the results of the trial (less than 10 days
             prior to study drug administration or expected during the trial)

          -  Participation in another trial with an investigational drug (less than 2 months prior
             to administration or expected during trial)

          -  Smoker (more than 10 cigarettes/day or more than 3 cigars/day or more than 3
             pipes/day)

          -  Alcohol abuse (more than 60 g of ethanol per day)

          -  Drug abuse

          -  Blood donation or loss greater than 400 mL (less than 1 month prior to administration
             or expected during the trial)

          -  Clinically relevant laboratory abnormalities
Clinical trial NCT01841112 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: bi 409306, bi 409306, bi 409306, bi 409306, placebo, placebo, bi 409306
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Healthy male Chinese and Japanese volunteers

          2. Age between 20 and 45 years

          3. BMI between 18.5 and 25 kg/m2 (Body Mass Index)

          4. Known genotype as specified in the study protocol

          5. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

        1. Any deviation from healthy condition